Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEMASURE (HMSR) - Buyout in the works? -- Ignore unavailable to you. Want to Upgrade?

To: bruce bell who wrote (45)	5/18/1998 11:58:00 AM
From: hcm1943	Read Replies (1) \| Respond to of 88

Symbol(s) HMSR-U & Date Use Page Up, Page Down, +, -, or press U -------------------------------------------------------------------------------- 05/18 9:33A (DJ) +HemaSure Files 510K With FDA For r/LS System >HMSR Story 1672 (HMSR, SEPR, I/BTC, I/DRG, I/MTC, G/FDA, N/DJN, N/DJWI, N/RND...) (MORE) DOW JONES NEWS 05-18-98 09:33 AM Story 2030 HemaSure - 510K Filing -2: r/LS System Filters Blood >HMSR MARLBOROUGH, Mass. (Dow Jones)--HemaSure Inc. (HMSR) filed a 510(k) premarket notification application with the Food and Drug Administration for its r/LS System. In a press release Monday, the company said the r/LS system is designed to increase the safety of donated blood by reducing leukocytes, or white blood cells, in red blood cell concentrates. HemaSure's 510(k) application for the r/LS System includes both human clinical and laboratory data. Leukocytes can cause adverse reactions in patients receiving blood transfusions, such as fever, chills, immune system suppression and immunological responses that can lead to patient rejection of subsequent blood transfusions. Also, leukocytes can carry and transmit harmful viruses, such as Hepatitis B and C, Epstein-Barr and CMV. HemaSure develops and delivers filtration technologies for processing blood components. (END) DOW JONES NEWS 05-18-98 10:26 AM